Article Text
Statistics from Altmetric.com
QUESTION: In patients with stable angina and additional risk factors, is nicorandil more effective than placebo for reducing coronary events?
Design
Randomised (allocation concealed*), blinded (clinicians and patients),* placebo-controlled trial with mean follow up of 1.6 years.
Setting
226 UK centres (primary care and hospital practices).
Patients
5126 patients (mean age 67 y, 76% men) who had stable angina with a history of myocardial infarction (MI), coronary bypass surgery, a definite diagnosis (by angiography) of coronary heart disease (CHD), or a documented positive result on the exercise test. Patients with CHD or a positive result on the exercise test were also required to have additional risk factors, including left ventricular ejection fraction ≤45%, echocardiographical end-diastolic dimension >55 mm, and type 1 or type 2 diabetes. Patients receiving treatment with a sulfonylurea were …
Footnotes
-
Sources of funding: Merck Pharmaceuticals; Aventis Pharma; Chugai Pharmaceutical Company.
-
For correspondence: Professor H J Dargie, Western Infirmary, Glasgow, UK. Email h.dargie{at}bio.gla.ac.uk.